Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines

Dong Hyeon Lee1, Kyu Sang Park2, In Deok Kong2, Jun Woo Kim1 and Bok Ghee Han*1

Address: 1Biobank for Health Sciences, Center for Genome Sciences, National Institute of Health, Korea Center for Disease Control and Prevention, Seoul, South Korea and 2Department of Physiology, Institute of Basic Medical Science, Yonsei University, Wonju College of Medicine, Wonju, South Korea

Email: Dong Hyeon Lee - hepatichyeon@paran.com; Kyu Sang Park - qsang@yonsei.ac.kr; In Deok Kong - kong@yonsei.ac.kr; Jun Woo Kim - jwkim69@empal.com; Bok Ghee Han* - bokghee@nih.go.kr

* Corresponding author

Abstract

Background: Epstein-Barr virus (EBV) infection immortalizes primary B cells in vitro and generates lymphoblastoid cell lines (LCLs), which are used for several purposes in immunological and genetic studies. Purinergic receptors, consisting of P2X and P2Y, are activated by extracellular nucleotides in most tissues and exert various physiological effects. In B cells, especially EBV-induced LCLs, their expression and function have not been well studied. We investigated the expression of P2 receptors on primary human B cells and LCLs using the quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) method for revealing the gene expression profile of the P2 receptor subtypes and their changes during transformation.

Results: The mRNA transcripts of most P2 receptors were detected in primary B cells; the expression of P2X3 and P2X7 receptors was the lowest of all the P2 receptors. By contrast, LCLs expressed several dominant P2 receptors – P2X4, P2X5, and P2Y11 – in amounts similar to those seen in B cells infected with EBV for 2 weeks. The amount of most P2 subtypes in LCLs or EBV-infected B cells was lower than in normal B cells. However, the amount of P2X7 receptor expressed in LCLs was higher. Protein expression was studied using Western blotting to confirm the mRNA findings for P2X1, P2X4, P2X7, P2Y1, and P2Y11 receptors. ATP increased the intracellular free Ca2+ concentration ([Ca2+]i) by enhancing the Ca2+ influx in both B cells and LCLs in a dose-dependent manner.

Conclusion: These findings describe P2 receptor expression profiles and the effects of purinergic stimuli on B cells and suggest some plasticity in the expression of the P2 receptor phenotype. This may help explain the nature and effect of P2 receptors on B cells and their role in altering the characteristics of LCLs.
The intracellular free Ca²⁺ concentration ([Ca²⁺]i). We were targeted [15,16].

Extracellular nucleotides – e.g., adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate, uracil 5'-triphosphate, and uracil 5'-diphosphate – have various physiological effects in many cells, such as exocrine and endocrine secretion, neurotransmission, cell proliferation, cell differentiation, and programmed cell death that are mediated by P2 receptors, consisting of P2X and P2Y receptors [5]. P2X receptors are ligand-gated cation channels, of which seven receptor subtypes (P2X₁ to P2X₇) have been identified and cloned [6]. P2Y receptors, which are G-protein-coupled metabotropic structures, consist of eight cloned and functionally distinct subtypes: P2Y₁, P2Y₂, P2Y₄, P2Y₆, P2Y₁₁, P2Y₁₂, P2Y₁₃, and P2Y₁₄ [5,7].

Blood cells express P2 receptors which regulate such responses as cell proliferation, differentiation, chemotaxis, cytokine release, immune and inflammatory responses [5,8]. In lymphocytes, ATP induces an increase in membrane permeability for cations and larger molecules [9,10], as well as cellular proliferation [11] and cell death through P2 receptors [12,13]. The precise nature of the expression and function of the P2 receptor subtypes have been investigated [14-16].

P2 receptors expressed in B cells have been investigated using electrophysiological, pharmacological, and immunocytochemical techniques, which have revealed the existence of P2 receptors [17], especially P2X [14,18]. However, the researchers in these studies failed to perform a quantitative analysis of P2 mRNA and used B cells from chronic lymphocytic leukemia (CLL) or LCLs, rather than pure B cells. Recently, the mRNA profile of the lymphocyte P2 receptor was subjected to quantitative analysis, but the B cells were not separated and not all subtypes were targeted [15,16].

In this study, we investigated the expression of P2 receptors in human B cells and in LCLs using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), Western blotting, and fluorimetric techniques to measure intracellular free Ca²⁺ concentration ([Ca²⁺]i). We were able to determine the profile of the P2 receptor mRNA in these cells and monitor changes in [Ca²⁺]i in response to P2 receptor activation. Our findings indicate the plasticity of P2 receptors in B cells during their transformation into LCLs.

Results

IgD and CD38 are cell-surface molecules that have been used widely to identify the B-cell phenotype during B-cell development. Like germinal center B cells, most EBV-transformed B cells were positive for CD38 but not for IgD [19,20]. The expression of IgD and CD38 molecules on primary B cells and EBV-transformed LCLs was evaluated by fluorescence-activated cell sorter (FACS) analysis. To generate LCLs, we cultured isolated B cells with the active EBV supernatant for 4 to 6 weeks, as described in Methods section. The primary B cells expressed IgD, but not CD38, and the LCLs expressed CD38, but not IgD (data not shown). This result is consistent with our previous findings [20].

P2 receptor mRNA quantification

The expression of P2 receptors in B cells and LCLs was determined using quantitative RT-PCR. The expression of the P2 receptor subtypes was compared among B cells, LCLs, and peripheral blood mononuclear cells (PBMCs). P2X₁ or P2Y₁ were used as a calibrator (i.e. the P2X receptor was expressed as a ratio of P2X, and the P2Y receptor as P2Y₁) in order to illustrate the expression of P2 receptors relative to each other. All P2X and P2Y receptor subtypes were detected in the B cells. Most of the P2 receptor subtypes had similar rates of expression within 1- or 2-fold of each other with the exception of the P2X₃ and P2X₇ receptors, which were expressed in lower quantities (Figure 1, n = 4). P2X₇ receptor expression was significantly low compared to other P2X receptors (p < 0.05), with the exception of P2X₃. The presence of P2X- and P2Y-receptor mRNA in the B cells is in agreement with the findings of previous lymphocyte studies using RT-PCR [15,16]. EBV-infected B cells were also examined because an in vitro transformation might alter the expression of receptors. The most abundant P2 receptor subtypes were P2X₄, P2X₅, and P2Y₁₁ (Figure 2; n = 4). The expression of P2X₄ receptors in LCLs was significantly higher than other P2X receptors (p < 0.05; Figure 2). The P2 receptors in B cells were compared with those expressed in LCLs (Figure 3, P2X₁ of B cells used as a P2X calibrator and P2Y₁ as a P2Y calibrator). The expression of the P2X₁ through to P2X₆ receptors and P2Y receptors in LCLs and B cells that had been infected with EBV for 2 weeks was significantly lower than in noninfected B cells (p < 0.01; Figure 3). However, the LCLs expressed a significantly larger number of P2X₇ receptors than B cells (p < 0.01; Figure 3). The expression of EBV-infected LCLs, which had been infected for more than 4 weeks and EBV-infected B cells, which had been infected for 2 weeks, yielded similar profiles and quantities. As a control, P2 receptors in PBMCs were quantified and these showed a different expression profile. In PBMCs, which are mainly monocytes and lymphocytes, P2X₄, P2Y₆, P2Y₁₁, and P2Y₁₃ were the predominant P2 receptor subtypes (Figure 4, n = 4), and the expression
rates for P2X_4 and P2Y_6 were significantly higher than other P2X or P2Y subtypes \( (p < 0.001) \). In addition, P2X_4, P2X_7, P2Y_4, P2Y_6, P2Y_11, P2Y_13, and P2Y_14 expression was significantly higher in PBMCs compared with B cells \( (p < 0.05) \), which may be the result of T cell/monocyte contamination in the PBMC preparation \[15,16\]. Therefore, the up-regulated P2X_7 receptor can be expected to have a physiological role during the transformation of B cells into LCLs.

**Western blotting for P2 receptors**

To investigate the correlation of mRNA with protein, we carried out Western blot analysis for P2X_1, P2X_4, P2X_7, P2Y_1, and P2Y_11 receptors, all of which had varying amounts of mRNA during EBV transformation \( (n = 4) \). The distribution of P2 receptors in B cells and LCLs is shown on the left panel (Figure 5). The bands representing P2X_1 (60-kDa), P2X_4 (65-kDa), P2Y_1 (66-kDa), and P2Y_11 (50-kDa) receptors were more prominent in B cells than in LCLs, which correlates with the results of the mRNA quantitative analysis. As for the P2X_7 receptor, it was represented by a prominent 68-kDa band in LCLs and a faint band in B cells. This is consistent with the results of RT-PCR, which indicated that the expression of P2X_7 is higher in LCLs than in B cells. To compare protein loading, the blot was re-probed with anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (40-kDa) (Figure 5, right).

**Effect of ATP on intracellular free Ca\(^{2+}\) concentration**

Extracellular ATP is an effective modulator of \([\text{Ca}^{2+}]_i\), and its activities are mediated through P2 receptors \[17\]. To determine whether the P2 receptors examined by RT-PCR
and Western blotting were functional, we carried out digital fluorescence imaging of the Ca\(^{2+}\)-sensitive dye Fura 2-AM and compared the images seen following ATP-induced changes in [Ca\(^{2+}\)]\(_i\) in B cells and LCLs. In the presence of 2 mM Ca\(^{2+}\) and 1 mM ATP, we observed an average increase in [Ca\(^{2+}\)]\(_i\) from 0.1 to 0.5 (representing the F340:F380 ratio) in B cells and LCLs (Δratio of B cells: 0.32 ± 0.04, \(n = 6\); Δratio of LCLs: 0.39 ± 0.04, \(n = 6\)) (Figures 6A and 6B). The [Ca\(^{2+}\)]\(_i\) increased with ATP in a dose-dependent manner (100–1000 μM; \(n = 25\)) (Figure 6C), indicating that the potency of ATP was similar in both cells. The mechanism leading to the intracellular Ca\(^{2+}\) response was examined further by repeating these experiments under Ca\(^{2+}\)-free conditions. The B cells were treated with 1 mM ATP under Ca\(^{2+}\)-free conditions, and the [Ca\(^{2+}\)]\(_i\) remained at or near the pre-agonist levels (Figure 7A). The peak [Ca\(^{2+}\)]\(_i\) was mostly abolished in B cells (\(n = 14\), \(p < 0.0001\)) and in LCLs (\(n = 12\), \(p < 0.0001\)) in the absence of Ca\(^{2+}\) (figure 7B). These data suggest that an influx of Ca\(^{2+}\) is the major route by which B cells and LCLs respond to ATP stimulation.

**Discussion**

In this study, we determined and compared mRNA expression levels for all known P2X and P2Y receptor subtypes on human B cells and LCLs. Quantitative RT-PCR was used to determine the gene expression profile for P2 receptors. This method was selected because selective agonists and antagonists for most of the P2 receptor subtypes are absent and real-time PCR has advantages over other methods, such as requiring only a small number of cells and being one of the most reliable methods of determining the amount of RNA.

This is the first study to show the expression of P2 receptors using mRNA from healthy human B cells. In these cells, most of the P2X and P2Y receptor subtypes had 2-
fold expression with the exception of P2X<sub>3</sub> and P2X<sub>7</sub> receptors. In the studies of the P2X receptor, the P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>4</sub>, and P2X<sub>7</sub> receptors were found in human B cells by an immunocytochemical assay [14] and the non-desensitizing cation channels activated by ATP, which is a feature of P2X<sub>7</sub> receptor, were measured using electrophysiological methods [18]. The different results of P2X subtype expression might be due to the different B cells, or variations in P2X receptor expression [21]. B cells transformed by EBV [18] or malignant B cells [14] were used in previous studies, while normal B cells were used in the present study. In addition, it is possible that there might be differences in the transcription, translation, and function of P2X receptors. The different P2X<sub>7</sub> expression levels may be because P2X<sub>7</sub> receptor might be up-regulated in CLLs [10] and that some lymphoid cells do not express

**Figure 5**

P<sub>2</sub> receptors (P2X<sub>1</sub>, P2X<sub>4</sub>, P2X<sub>7</sub>, P2Y<sub>1</sub>, and P2Y<sub>11</sub>) compared by Western blotting in B cells and LCLs. Proteins extracted from B cells and LCLs were probed with rabbit polyclonal antibodies directed against P2X<sub>1</sub> (60-kDa), P2X<sub>4</sub> (65-kDa), P2X<sub>7</sub> (68-kDa), P2Y<sub>1</sub> (66-kDa), and P2Y<sub>11</sub> (50-kDa) (left). Membranes were re-probed by GAPDH (40-kDa) (right). Data are representatives of 4 independent experiments.
P2X7 receptor [11]. In addition, B cells did not undergo the typical increase in membrane permeability to ATP and were not susceptible to ATP-mediated cytotoxicity [8,22]. Although the P2Y receptors in B cells were investigated, it was not enough to compare the expression of subtypes. P2Y subtypes were detected by RT-PCR in previous studies, albeit only in lymphocytes [15,16].

In LCLs and B cells infected by EBV for 2 weeks, the predominant P2 receptor subtypes were P2X1, P2X4, P2X5, P2X7, and P2Y11. The expression of most P2 receptors was suppressed during the EBV-induced B-cell transformation into LCLs, however, the suppression of P2X1, P2X4, P2X5, and P2Y11 receptors was not as great as for other subtypes.

Figure 6
Comparison of ATP-induced increases in [Ca2+]i in B cells and LCLs. (A, B) Average time courses for Ca2+ responses to P2 receptor stimulation with ATP (1 mM) in B cells (A, n = 6) and in LCLs (B, n = 6). ATP was applied as indicated by the horizontal bars above the traces. (C) Concentration-response curve for the increase in [Ca2+]i in response to ATP in B cells and in LCLs (Δratio F340/F380). ATP increased [Ca2+]i in a dose-dependent manner. The maximum increase in the [Ca2+]i over basal is plotted against the concentration of ATP. The measurement of [Ca2+]i was carried out in single cells attached to a coverslip, as described in the Methods section. Data are the mean ± SEM for at least 25 cells on 4 to 5 coverslips.

Figure 7
Effect of extracellular Ca2+-free conditions on [Ca2+]i induced by ATP. (A) Average time courses for Ca2+ responses induced by external perfusion of ATP (1 mM) in normal solution and the Ca2+-free solution in B cells (n = 4). Agent was applied as indicated by the horizontal bars above the traces. (B) Peak of ATP-induced [Ca2+]i rises during pretreatment with the Ca2+-free solution (n = 14 for B cells; n = 12 for LCLs). Data are the mean ± SEM; *p < 0.0001 compared to Ca2+ treated samples.
Only P2X4 receptor was significantly up-regulated. Western blotting showed similar patterns for P2X1, P2X4, P2X7, P2Y1, and P2Y11, as well as for P2X2, P2X6, P2Y6, and P2Y4 (data not shown). Our results suggest that there is some plasticity in P2-receptor expression in B cells. This possibility has been investigated in many tissues and cells, including the urinary bladder, heart, vessels, gut, neurons, and cancer cells [5]. In immune cells, plasticity in P2Y2 receptor expression was studied during myeloid leukocyte differentiation [23]. Sensitivity to ATP in thymocytes changes with the stage of maturation [24,25], and P2X receptor expression can be modulated by diverse stimuli [26]. The plasticity of P2 receptors may be due to changes in their exposure to ATP or EBV-induced changes in gene expression. In vivo, ATP is often released by blood cells into the extracellular environment through nonlytic mechanisms. Some leakage of cytoplasmic ATP may also occur as a consequence of damage to the cell or acute cell death. Platelet-dense granules comprise another relevant source of ATP [8]. In vitro, however, the sources of ATP for B cells are limited to nonlytic mechanisms or leakage of cytoplasmic ATP. The EBV-induced transformation of B cells into LCLs results in some B cells dying, which results in ATP being released into the extracellular compartment, where it continually degrades. Thus, the concentration of ATP may be high in the early stages of in vitro transformation and lower in later stages. The expression of P2 receptors may be affected by this fluctuation in environmental ATP.

In PBMC populations that include lymphocytes and monocytes, the dominant P2 receptor subtypes were P2X4, P2Y6, P2Y11, and P2Y13. An mRNA expression assay revealed that the P2Y1, P2Y2, P2Y4, and P2Y6 receptors were expressed in lymphocytes and monocytes and that the P2Y6 receptor was expressed in relatively higher amounts than the other P2Y receptor subtypes [16]. P2X4 and P2Y11 receptors were expressed in relatively large amounts in lymphocytes and P2X4, P2Y2, and P2Y13 receptors in monocytes [15]. The expression of P2X4, P2Y6, and P2Y13 receptors correlated with the findings of previous studies; however, the expression of the P2Y11 receptor was somewhat different. It is possible that other lymphocytes or monocytes expressed these subtypes predominantly. Alternatively this may reflect a variation in cohorts or contamination with other types of blood cells. To date, these blood cells have not been investigated well enough to compare P2 receptor subtypes, although some of them have been surveyed [5,8,16,27,28]. Because the P2 receptor profiles of blood cells are not completely known, it is difficult to determine which P2 receptor subtypes have been expressed dominantly in PBMCs until now.

Although the P2Y6 and P2Y10 receptors were examined with other subtypes, the findings for these subtypes were omitted because they are not included among the classical P2Y receptor subtypes in humans. We found the mRNA for these subtypes in B cells, LCLs, and PBMCs, indicating that they are prominent in these cells. In previous studies of human P2 receptors, the P2Y2 and P2Y10 receptors were expressed in HL60 [29] and included in the human genome [30]. The National Center for Biotechnology Information (NCBI) confirmed the gene sequence for each of these receptors (P2Y6: NM_178129, P2Y10: NM_014499). A physiological role for the P2Y6 and P2Y10 receptors in B cells and in human blood cells can therefore be expected.

ATP-stimulated P2 receptors increased the [Ca2+]i in B cells and LCLs, albeit rather slowly. This was quite a different effect from that of other stimuli, such as the anti-IgM antibody, which caused [Ca2+]i levels to change rapidly [31]. This might be due to differences in Ca2+ signaling or the temperature at which the experiments were conducted, which might influence the kinetics involved when the [Ca2+]i changes. Extracellular Ca2+-free conditions prevented the [Ca2+]i from increasing, thereby indicating that the main cause of the increase in [Ca2+]i might be an ATP-induced influx of Ca2+, although the possibility that mobilization of stored Ca2+ may be involved should probably also be considered. The increase in [Ca2+]i might be largely due to P2X receptor activity, because it was mediated by an influx of Ca2+, which is the major effect of activating P2X receptors. The results of real-time PCR indicated a decrease in P2 receptors and those of Western blotting demonstrated a similar pattern for several P2 receptors, even when the up-regulation of P2X7 receptor was considered. However, the increase in [Ca2+]i by ATP was a little higher in LCLs than in B cells, which was not statistically significant. EBV-transformed B cells might enhance the availability of Ca2+, thereby causing [Ca2+]i to rise, even when P2 receptors are down-regulated. The response to extracellular ATP is an increase in [Ca2+]i in B cells as well as in LCLs, which are probably derived from EBV-infected B cell lymphoma in vivo. This may cause a variety of cellular events, ranging from transcriptional regulation to cell migration and proliferation.

**Conclusion**

In this study, the expression of P2X and P2Y receptors in human B cells and LCLs was investigated. P2-receptor expression was suppressed during the EBV-induced transformation of B cells, except for the P2X5 subtype, which was up-regulated. Extracellular ATP induced an increase in [Ca2+]i in B cells and LCLs via P2 receptors. Therefore, these findings reveal the exact P2 receptor profiles and the effects of purinergic stimuli on B cells and suggest some plasticity in the expression of the P2 receptor phenotype.
This will help us explain the nature and effect of P2 receptors on B cells and their role in altering the characteristics of LCLs.

**Methods**

**B-cell purification and generation of EBV-transformed LCLs**

Ten 240-mL packs of blood were obtained from the Central Red Cross Blood Center (Seoul, Korea). This blood was not appropriate for transfusion because of slightly elevated alanine aminotransferase levels. We used it to isolate PBMCs, using Ficoll-Hypaque gradient centrifugation (Amersham Biosciences, Uppsala, Sweden) and B cells, which were purified (> 95% CD20+) using a B-cell isolation kit and a MACS separator (Miltenyi Biotec, Bergisch Gladbach, Germany). The immortalization of B cells was achieved by EBV infection [2,32-34]. The B95-8 supernatant was added to the purified B cells in a culture flask (1 x 10^6 cells/mL). Following a 2-hour incubation period at 37°C, the same volume of medium and 0.5 μg/mL cyclosporine A [35] were added. The cultures were incubated for 4 to 6 weeks until clumps of EBV-infected B cells were visible. EBV-transformed LCLs were cultured in RPMI-1640 medium (GIBCO/BRL, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (BioWhittaker, Walkerville, MD, USA) and 1% (v/v) antibiotics/antimycotics that included penicillin G (100 IU/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL). The cells were cultured in a humidified atmosphere of 5% CO₂ and 95% air at 37°C. The EBV stock was prepared from an EBV-transformed B95-8 marmoset cell line. These cells were grown in an RPMI-1640 medium supplemented with 10% FBS, and infectious culture supernatants were harvested and stored at -80°C until needed. Thus, each pack of blood was used to produce B cells, EBV-infected B cells, LCLs, and PBMCs for use in this experiment. The study was approved by the Institutional Review Board at the National Institute of Health, Korea Center for Disease Control and Prevention.

**Quantitative real-time RT-PCR**

The total cellular RNA was collected from human B cells, LCLs, and PBMCs. RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions and stored at -80°C until used. Quantitative RT-PCR was performed to determine the expression of the P2 receptor genes (Table 1). To generate cDNA, we induced reverse transcription of the total RNA using oligo(dT)₁₅ (Roche Diagnostics GmbH, Mannheim, Germany) and reverse transcription polymerase (Promega, Madison, WI, USA). Oligonucleotide primers (Bioneer, Daejeon, Korea) were designed using Primer Express software (Applied Biosystems, Foster City, CA, USA), based on sequences obtained from the GenBank database, and tested for quality and efficiency. Primer efficiency was established to ensure optimal amplification of our samples. Serial dilutions of synthetic cDNAs were carried out according to the supplier's instructions to define relative changes in quantity. Real-time PCR was performed using SYBR Green PCR Master mix (Applied Biosystems) in an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). The amplification program included activation of AmpliTaq Gold at 95°C for 10 minutes, followed by 45 cycles of 2-step PCR with denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 1 minute. Amplifications were followed by a melting curve analysis. A negative control (no cDNA template) was run simultaneously with every assay. The PCR from each cDNA sample was run in triplicate. Constitutively expressed GAPDH was selected as an endogenous control to correct any potential variation in RNA loading or in the efficiency of the amplification reaction. Results are presented as relative fold changes by using GAPDH as a reference and P2X₇ or P2Y₁ as a calibrator and applying the formula 2^-ΔΔCt [36].

**Western blotting**

Cells were lysed in RIPA buffer containing 150 mM NaCl, 50 mM Tris-Cl (pH 7.2), 1% sodium deoxycholate, 0.1% SDS, 1 μg/mL aprotinin, 1 mM EDTA, 1 mM EGTA, and 1 mM sodium orthovanadate. After incubation in ice for 20 minutes on a shaking platform, the samples were centrifuged at 10,000 × g for 5 minutes at 4°C. Proteins were mixed with the sample buffer (50 mM Tris-Cl, pH 6.8, 10% glycerol, 2% SDS, 1% mercaptoethanol, and 0.1% bromophenol blue), heated to 95°C for 5 minutes, and separated on a 10% SDS-PAGE gel. The gel was transferred to polyvinylidene difluoride membranes (Amersham Pharmacia Biotech, Buckinghamshire, UK) and blocked in TBST (20 mM Tris-Cl, pH 7.6, 137 mM NaCl, 2.7 mM KCl, and 0.1% Tween 20) containing 5% (v/v) nonfat milk powder for 2 hours at room temperature. The membrane was incubated with rabbit polyclonal antibodies (Alo- mone Labs, Jerusalem, Israel) against P2X₇ receptor, P2X₄ receptor, P2X₃ receptor, P2Y₁ receptor, or P2Y₁₁ receptor in TBST for 2 hours at room temperature, washed with TBST, and incubated with secondary anti-rabbit IgG (Amersham Pharmacia Biotech) in TBST for 1 hour. After the membrane was washed in TBST, protein bands were visualized using Western Lightning (PerkinElmer Life Sciences Inc., Gaithersburg, MD, USA). To compare protein loading, the blot was re-probed with anti-GAPDH antibody (Novus Biologicals, Littleton, CO, USA).

**Intracellular Ca²⁺ measurements**

The [Ca²⁺]₀ was measured using a single-cell microscopy technique with Fura 2 [31,37]. B cells and LCLs were suspended in culture and allowed to attach to glass coverslips coated with Poly-L-lysine (100 μg/mL; Sigma-Aldrich, St. Louis, MO, USA) and incubated for at least 3 hours before...
use. The cells were loaded with the cell-permeable Ca\(^{2+}\) indicator Fura 2-AM (5.0 μM; Molecular Probes, Eugene, OR, USA) in the culture medium for 1 hour at room temperature and then washed and bathed in an external solution (135 mM NaCl, 5 mM KCl, 2 mM CaCl\(_2\), 1 mM MgCl\(_2\), 10 mM glucose, and 10 mM HEPES at pH 7.4) for at least 20 minutes before Ca\(^{2+}\) measurements were made. Glass coverslips were placed into a chamber (Warner Instrument, Hamden, CT, USA) on an inverted microscope (Olympus, Tokyo, Japan), and the fluorescence intensities of the Fura-2-loaded cells were measured using a digital fluorescence imaging system. Discrete bandwidth excitation light (340 nm, 380 nm) was delivered to the epifluorescence attachment of the microscope through a quartz fiber-optic guide. The fluorescence emitted by the Fura-2-loaded cells was passed through a 510-nm-long pass filter, and images were obtained using a cooled charge-coupled device camera (Roper Scientific, Trenton,

### Table 1: Sequence details for all P2X and P2Y receptor subtypes and reference (GAPDH) primers.

| Receptor/Gene accession | Direction | Sequence | Position |
|-------------------------|-----------|----------|----------|
| **P2X\(_1\)**          | Forward   | 5'-CGCCTTCCTCTCTTGAGTATGA-3' | 471 – 491 |
| **NM_002558**          | Reverse   | 5'-AGATAACGCCACCTCTTTATTACG-3' | 538 – 514 |
| **P2X\(_2\)**          | Forward   | 5'-GCCTACGGGATCCGCATT-3' | 958 – 975 |
| **NM_170682**          | Reverse   | 5'-TGGTGAACTGAGCTGAAC-3' | 1024 – 1005 |
| **P2X\(_3\)**          | Forward   | 5'-GCTGGAACCATCGGGATCA-3' | 135 – 152 |
| **NM_002559**          | Reverse   | 5'-GAAAACCAACCTACGTTAAGA-3' | 205 – 182 |
| **P2X\(_4\)**          | Forward   | 5'-CCTCTGCTTGCCACAGTACT-3' | 1108 – 1128 |
| **NM_002560**          | Reverse   | 5'-CCAGGAGATCCTGTTGCTCA-3' | 1176 – 1155 |
| **P2X\(_5\)**          | Forward   | 5'-CTGCCCTGCTTGCTGTCG-3' | 311 – 328 |
| **NM_002561**          | Reverse   | 5'-GCAGGCCACCTCTTTGTTT-3' | 378 – 360 |
| **P2X\(_6\)**          | Forward   | 5'-AAGCCAGTCTGTTGTTCA-3' | 480 – 497 |
| **AF0565385**          | Reverse   | 5'-TCTCCACTGCGGACCAACTC-3' | 555 – 536 |
| **P2X\(_7\)**          | Forward   | 5'-TCTTCAGTGAGCAAACTTTTCTCA-3' | 401 – 425 |
| **NM_002562**          | Reverse   | 5'-GTCTCTCGGGAGGATAC-3' | 476 – 458 |
| **P2Y\(_1\)**          | Forward   | 5'-CGTCTGCTTGTTGATCATT-3' | 1352 – 1370 |
| **NM_002563**          | Reverse   | 5'-GGACCCCGTACCTGAAGTA-3' | 1419 – 1399 |
| **P2Y\(_2\)**          | Forward   | 5'-GAACGTGACATCGGAGAAGGA-3' | 1495 – 1520 |
| **NM_176072**          | Reverse   | 5'-GCCGCGCTGGACTCTGT-3' | 1567 – 1531 |
| **P2Y\(_4\)**          | Forward   | 5'-CCTGGAGTTGTGCAAGTA-3' | 725 – 742 |
| **NM_002565**          | Reverse   | 5'-TGACCCGGCCAGCTGAG-3' | 793 – 776 |
| **P2Y\(_6\)**          | Forward   | 5'-GCGGGGCGGCACAGGCA-3' | 1171 – 1168 |
| **NM_176797**          | Reverse   | 5'-GACCTCTGCTCTGTCCAT-3' | 1227 – 1209 |
| **P2Y\(_{11}\)**       | Forward   | 5'-GTGGAGCGGCTCTGGTCT-3' | 511 – 530 |
| **NM_002566**          | Reverse   | 5'-GTTAGCGGGTGGAGCTGAG-3' | 586 – 567 |
| **P2Y\(_{12}\)**       | Forward   | 5'-AGTCTCTTCCTTCCCAGTCTA-3' | 318 – 339 |
| **NM_022788**          | Reverse   | 5'-CATCGCCGACCGCATTG-3' | 385 – 368 |
| **P2Y\(_{13}\)**       | Forward   | 5'-GAGCACTGCTGGAATCGATACAGCTGTGTA-3' | 223 – 248 |
| **NM_023914**          | Reverse   | 5'-GCAGGATGCCGGTGCAAGA-3' | 291 – 274 |
| **P2Y\(_{14}\)**       | Forward   | 5'-TTCTTCTCAAGAATCTTGGTCACT-3' | 433 – 456 |
| **NM_014879**          | Reverse   | 5'-GCAGACGACCTGCAAACA-3' | 505 – 486 |
| **GAPDH**              | Forward   | 5'-CCACCCATGCAAATTC-3' | 227 – 244 |
| **NM_002046**          | Reverse   | 5'-TGGGATTCTTCCATGAGAAG-3' | 295 – 274 |
NJ, USA). Fluorescent video images were averaged, digitized (0.3–1.0 Hz), and analyzed using Metafluor acquisition and analysis software (Universal Imaging Corp, West Chester, PA, USA). Individual cells in the field of view were selected and paired 340/380 images were subtracted from the background. The Fura-2 fluorescence ratios, indicative of changes in [Ca$$^{2+}$$], were calculated and their changes were extracted over time. All experiments were performed at room temperature, and the external solution and drugs were perfused at a rate of 2 mL/min by gravity.

Data were expressed as the ratio of fluorescence due to drugs and drugs were perfused at a rate of 2 mL/min by gravity.

All experiments were performed at room temperature, and the external solution and drugs were perfused at a rate of 2 mL/min by gravity.

Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation.

BGH oversaw the collection and analysis of data and the manuscript. IDK originated the idea for the research and revised the manuscript. JWK collected the data and participated in writing the

BMC Immunology 2006, 7:22

http://www.biomedcentral.com/1471-2172/7/22

References

1. Pope JH: Establishment of cell lines from peripheral leucocytes in infectious monoclonosis. Nature 1967, 216:810-811.

2. Neitzel H: A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hem Genet 1986, 73:320-326.

3. Carter KL, Cahir-McFarland E, Kieff E: Epstein-barr virus-induced changes in B-lymphocyte gene expression. J Virol 2002, 76:10427-10435.

4. Wronlewski JM, Coppol A, Batson LP, Landers CD, Yannelli JR: Cell surface phenotyping and cytotoxic production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods 2002, 264:19-28.

5. Burnstock G, Knight GE: Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 2004, 240:31-304.

6. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, Humphrey PP: International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 2001, 53:107-118.

7. Foord SM, Bonner TI, Neubig RR, Rossor EM, Pin JP, Davenport AP, Spedding M, Harmar AJ: International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 2005, 57:279-288.

8. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, Torboli M, Bolognesi G, Baricordi OR: Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001, 97:587-600.

9. Gargett CE, Cornish JE, Wiley JS: ATP, a partial agonist for the P2 receptor family of human lymphocytes. Br J Pharmacol 1997, 122:911-917.

10. Wiley JS, Dubyak GR: Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes. Blood 1989, 73:1316-1323.

11. Bresserd OR, Melchiorri E, Adinolfi E, Falzoni S, Chiozzi P, Buell G, Di Virgilio F: Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem 1999, 274:33206-33208.

12. Zanovello P, Bronte V, Rosato A, Pizzo P, Di Virgilio F: Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J Immunol 1990, 145:1545-1550.

13. Gu BJ, Zhang W, Worthington RA, Sleyter R, Diao-Ung P, Petrou S, Barden JA, Wiley JS: A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001, 276:11135-111142.

14. Sleyter R, Barden JA, Wiley JS: Detection of P2X purinergic receptors on human B lymphocytes. Cell Tissue Res 2001, 241:231-236.

15. Wang L, Jacobsen SE, Bengtsson A, Erlande D: P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004, 5:16.

16. Jin J, Daasi VR, Sistare FD, Kunapuli SP: Distribution of P2Y receptor subtypes on haematopoietic cells. Br J Pharmacol 1998, 123:789-794.

17. Padeh S, Cohen A, Roifman CM: ATP-induced activation of human B lymphocytes via P2-purinoceptors. J Immunol 1991, 146:1626-1632.

18. Bresser Schneider F, Klapperstuck M, Lohn M, Markwardt F: Nonspecific cationic currents elicited by extracellular ATP in human B lymphocytes. Pflugers Arch 1995, 429:691-698.

19. Pasquali V, Liu YJ, Magalski A, de Boutetierle O, Banchereau J, Capra JD: Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 1994, 180:329-339.

20. Hur DY, Lee MH, Kim JW, Shin YK, Rho JK, Kwack KB, Lee WJ, Han KG: CD19 signalling improves the Epstein-Barr virus-induced immortalization of human B cells. Cell Prolif 2005, 38:35-45.

21. Skarzynski KK, Fuller SJ, Sleyter R, Diao-Ung LP, Gu BJ, Wiley JS: A 5' intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1–2% of the Caucasian population. FEBS Lett 2005, 579:2675-2678.

22. Wiley JS, Chen R, Jamieson GP: The ATP4A-receptor-operated channel (P2Z class) of human lymphocytes allows Ba2+ and ethidium+ uptake: inhibition of fluxes by suramin. Arch Biochem Biophys 1993, 305:54-60.

23. Clifford EE, Martin KA, Dalal P, Thomas R, Dubyak GR: Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5'-nucleotidase in myeloid leukocytes. Am J Physiol 1997, 273: C973-C987.

24. Chused TM, Apasov S, Sikovskys M: Murine T lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation. J Immunol 1996, 157:1371-1380.

25. Ross PE, Ehring GR, Cahanal MD: Dynamics of ATP-induced calcium signaling in single mouse thymocytes. J Cell Biol 1997, 138:987-998.
26. Humphreys BD, Dubyak GR: Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 1998, 64:265-273.

27. Sluyter R, Shemon AN, Barden JA, Wiley JS: Extracellular ATP increases cation fluxes in human erythrocytes by activation of the P2X7 receptor. J Biol Chem 2004, 279:44749-44755.

28. Tanneur V, Duranton C, Brand VB, Sandu CD, Akkaya C, Kasinathan RS, Gachet C, Sluyter R, Barden JA, Wiley JS, Lang F, Huber SM: Purinoceptors are involved in the induction of an osmolyte permeability in malaria-infected and oxidized human erythrocytes. FASEB J 2006, 20:i133-135.

29. Adrian K, Bernhard MK, Breitinger HG, Ogilvie A: Expression of purinergic receptors (ionotropic P2X1–7 and metabotropic P2Y1–11) during myeloid differentiation of HL60 cells. Biochim Biophys Acta 2000, 1492:127-138.

30. Cantagrel V, Lossi AM, Boulanger S, Depeetris D, Mattei MG, Gecz J, Schwartz CE, Van Maldergem L, Villard L: Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males. J Med Genet 2004, 41:736-742.

31. Mori Y, Wakamori M, Miyakawa T, Hermosura M, Hara Y, Nishida M, Hirose K, Mizushima A, Kurosaki M, Mori E, Gotoh K, Okada T, Feig A, Penner R, Iino M, Kurosaki T: Transient receptor potential I regulates capacitative Ca(2+) entry and Ca(2+) release from endoplasmic reticulum in B lymphocytes. J Exp Med 2002, 195:673-681.

32. Tohda H, Oikawa A, Kudo T, Tachibana T: A greatly simplified method of establishing B-lymphoblastoid cell lines. Cancer Res 1978, 38:3560-3562.

33. Nilsson K: Human B-lymphoid cell lines. Hum Cell 1992, 5:25-41.

34. Oh HM, Oh JM, Choi SC, Kim SW, Han WC, Kim TH, Park DS, Jun CD: An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes. Cell Prolif 2003, 36:191-197.

35. Pelloquin F, Lamelin JP, Lenoir GM: Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol 1986, 22:689-694.

36. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) Method. Methods 2001, 25:402-408.

37. Lievremont JP, Numaga T, Vazquez G, Lemonnier L, Hara Y, Mori E, Trebak M, Moss SE, Bird GS, Mori Y, Putney JW Jr: The role of canonical transient receptor potential 7 in B-cell receptor-activated channels. J Biol Chem 2005, 280:35346-35351.